000752830 000__ 03766cam\a2200529Mi\4500
000752830 001__ 752830
000752830 005__ 20230306141435.0
000752830 006__ m\\\\\o\\d\\\\\\\\
000752830 007__ cr\nn\nnnunnun
000752830 008__ 151118s2016\\\\fr\a\\\\o\\\\\000\0\eng\d
000752830 019__ $$a930082903$$a930760230$$a935247957
000752830 020__ $$a9782817804927$$q(electronic book)
000752830 020__ $$a2817804929$$q(electronic book)
000752830 020__ $$z9782817804910
000752830 020__ $$z2817804910
000752830 0247_ $$a10.1007/978-2-8178-0492-7$$2doi
000752830 035__ $$aSP(OCoLC)ocn932167141
000752830 035__ $$aSP(OCoLC)932167141$$z(OCoLC)930082903$$z(OCoLC)930760230$$z(OCoLC)935247957
000752830 040__ $$aNUI$$beng$$cNUI$$dOCLCO$$dCOO$$dOCLCF$$dN$T$$dIDEBK$$dYDXCP$$dGW5XE$$dEBLCP$$dOCL
000752830 049__ $$aISEA
000752830 050_4 $$aRC270.8
000752830 050_4 $$aRC254-282
000752830 08204 $$a616.994$$223
000752830 24500 $$amTOR inhibition for cancer therapy$$h[electronic resource] :$$bpast, present and future /$$cedited by Monica Mita, Alain Mita, Eric K. Rowinsky.
000752830 264_1 $$aParis :$$bSpringer,$$c2016.
000752830 300__ $$a1 online resource (vi, 300 pages) :$$billustrations.
000752830 336__ $$atext$$btxt$$2rdacontent
000752830 337__ $$acomputer$$bc$$2rdamedia
000752830 338__ $$aonline resource$$bcr$$2rdacarrier
000752830 347__ $$atext file$$bPDF$$2rda
000752830 504__ $$aIncludes bibliographical references.
000752830 5050_ $$aForward -- Past -- mTOR inhibitors: a little bit of history -- Present -- The mTOR pathway -- The evolving role of mTOR inhibitors in renal cell carcinoma -- The role of mTOR inhibitors in breast cancer -- The role of mTOR inhibitors in neuroendocrine tumors -- New indications of mTOR inhibitors in rare tumors -- The role of mTOR inhibitors in the treatment of hematological malignancies -- The clinical pharmacology and toxicity profile of rapalogs -- Resistance to mTOR inhibitors -- Rational combinations of mTOR inhibitors as anticancer strategies -- Future -- Predictive biomarkers of response to mTOR inhibitors -- The potential future indication of rapamycin analogs for the treatment of other solid tumors -- mTOR inhibition beyond rapalogs -- mTOR, aging and cancer: the missing link? -- New study design for mTOR inhibitors and other biological agents -- Future directions for the development of mTOR inhibitors.
000752830 506__ $$aAccess limited to authorized users.
000752830 520__ $$aThis book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs. Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compounds currently under evaluation.
000752830 650_0 $$aCancer$$xTreatment.
000752830 650_0 $$aMedicine.
000752830 650_0 $$aMolecular biology.
000752830 650_0 $$aHematology.
000752830 650_0 $$aOncology.
000752830 7001_ $$aMita, Monica.$$eeditor.
000752830 7001_ $$aMita, Alain.$$eeditor.
000752830 7001_ $$aRowinsky, Eric K.$$eeditor.
000752830 77608 $$iPrint version:$$z9782817804910
000752830 852__ $$bebk
000752830 85640 $$3SpringerLink$$uhttps://univsouthin.idm.oclc.org/login?url=http://link.springer.com/10.1007/978-2-8178-0492-7$$zOnline Access$$91397441.1
000752830 909CO $$ooai:library.usi.edu:752830$$pGLOBAL_SET
000752830 980__ $$aEBOOK
000752830 980__ $$aBIB
000752830 982__ $$aEbook
000752830 983__ $$aOnline
000752830 994__ $$a92$$bISE